Tag:
BioTie Therapies
Latest Headlines
Latest Headlines
Newron soars on positive PhIII results, $26M pact for Parkinson's drug
Despite being left at the M&A altar last fall after a key partnership deal collapsed, Newron says it has successfully completed two late-stage studies of its experimental Parkinson's drug.
PhIII placebo response complicates Lundbeck's case for anti-drinking drug
Lundbeck has taken the wraps off its Phase III data for the alcohol dependence drug nalmefene.
Lundbeck files app for alcohol dependence drug
Lundbeck has filed for European approval of Selincro, a new treatment for alcohol dependence. The Dutch company obtained the treatment in a 96 million euro licensing deal with Biotie . New late-stage
Biotie backs out of $63M Newron Pharma buyout
Newron Pharmaceuticals has been left at the altar. Finland's Biotie has decided to nix plans to acquire Newron after Merck Serono decided to give up rights to Newron's Parkinson's drug and lead
Biotie snares Newron CNS pipeline in $63M share/CVR deal
Finland's Biotie Therapies has struck a deal to acquire Newron Pharmaceuticals ( $NWRN ) for up to $63 million worth of shares. The tie-up--which includes a significant amount tied up in CVRs--creates
Biotie buys CNS developer Synosia in $121.5M deal
Finland's Biotie is buying CNS company Synosia for $121.5 million in an all-stock deal, creating a combined company with nine clinical-stage drug candidates. As part of the transaction, Biotie will
Lundbeck preps Phase III trials for alcoholism
Denmark's Lundbeck says it is ready to start Phase III trials for nalmefene, a drug designed to treat alcohol dependency. The developer says that it plans to recruit 1,800 patients for three
BioTie buys Germany's Elbion
Finland's BioTie Therapies has agreed to purchase German's Elbion, forming a company that will focus on CNS disorders and inflammatory diseases. BioTie gains ELB353, a Phase I anti-inflammatory drug,
